Michael Frumovitz, MD
Gynecologic Oncology · Houston, TXNPI 1326146341
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $131,982 of the $156,202 with a category attached, or 84.5%. Stryker accounts for 85.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $61,149 and has fallen 98.4% since, to $1,000 in 2024. Among gynecologic oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 95 payments — averaging $1644.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$133K
- Seagen Inc.$8K
- Biom'up SA$7K
- Merck$2K
- Genentech USA, Inc.$2K
- Alkermes, Inc.$2K
- plus $2K from 2 others
Across 2 payments — averaging $443,008 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$863K
- Kyowa Kirin, Inc.$23K
What the payments were for
- Consulting fees$131,98284%
- Travel & lodging$22,62614%
- Food & beverage$1,5831%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 72 | $132,938 |
| Seagen Inc. | 7 | $8,284 |
| Biom'up SA | 9 | $6,779 |
| Merck | 2 | $2,451 |
| Genentech USA, Inc. | 1 | $2,355 |
| Alkermes, Inc. | 1 | $1,650 |
| Johnson & Johnson(2 entities) | 2 | $1,645 |
| Momentis Surgical Inc. | 1 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPY-PHI SYSTEM$44,282
- 1688 HD 3 CHIP CAMERA$28,940
- SPY TECHNOLOGY$25,928
- 1588 HD 3 CHIP CAMERA$19,160
- DERMACELL$19,160
- 1688$15,650
- AIM LAPARASCOPES$14,122
- HEMOBLAST$6,631
- 1788$1,000
- NEW PRODUCT DEVELOPMENT$639
- Enseal$130
- ETHICON$130
- Harmonic$130
- Anovo Surgical System$100
How this compares
$156,202 in reported general payments places this provider in the 90th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Houston
- Robert ColemanHouston$864K
- Maurie MarkmanHouston$204K
- Aparna KamatHouston$116K
- Anuj SuriHouston$72K
- Anil SoodHouston$69K
- Pedro RamirezHouston$42K
- Pamela SolimanHouston$37K
- Anthony CostalesHouston$17K
- Travis SimsHouston$14K
- Lois RamondettaHouston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.